Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
Tóm tắt
Từ khóa
Tài liệu tham khảo
World Health Organization. Cancer fact sheet No. 297. http://www.who.int/mediacentre/factsheets/fs297/en/. Published 2012. Last accessed October 26, 2012
Miller, 2004, Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer, J Clin Oncol, 22, 1103, 10.1200/JCO.2004.08.158
Garassino, 2009, Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis, Anticancer Res, 29, 2691
Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753
Stinchcombe, 2008, Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?, Oncologist, 13, 933, 10.1634/theoncologist.2008-0019
Thatcher, 2005, Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer), Lancet, 366, 1527, 10.1016/S0140-6736(05)67625-8
Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699
Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945
Boland, 2009, Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas, Hum Pathol, 40, 1152, 10.1016/j.humpath.2009.01.012
Inamura, 2008, EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers, J Thorac Oncol, 3, 13, 10.1097/JTO.0b013e31815e8b60
Inamura, 2009, EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset, Mod Pathol, 22, 508, 10.1038/modpathol.2009.2
Koivunen, 2008, EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer, Clin Cancer Res, 14, 4275, 10.1158/1078-0432.CCR-08-0168
Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448
Paik, 2011, Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization, J Thorac Oncol, 6, 466, 10.1097/JTO.0b013e31820b82e8
Rodig, 2009, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population, Clin Cancer Res, 15, 5216, 10.1158/1078-0432.CCR-09-0802
Salido, 2011, Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer, J Thorac Oncol, 6, 21, 10.1097/JTO.0b013e3181fb7cd6
Shaw, 2009, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK, J Clin Oncol, 27, 4247, 10.1200/JCO.2009.22.6993
Shaw, 2011, Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis, Lancet Oncol, 12, 1004, 10.1016/S1470-2045(11)70232-7
Shinmura, 2008, EML4-ALK fusion transcripts, but no NPM-. TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas, Lung Cancer, 61, 163, 10.1016/j.lungcan.2007.12.013
Kim, 2011, Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression, J Thorac Oncol, 6, 1359, 10.1097/JTO.0b013e31821cfc73
Hillier, 2011, FORM: an Australian method for formulating and grading recommendations in evidence-based clinical guidelines, BMC Med Res Methodol, 11, 23, 10.1186/1471-2288-11-23
Merlin, 2009, Extending an evidence hierarchy to include topics other than treatment: revising the Australian ‘levels of evidence', BMC Med Res Methodol, 9, 34, 10.1186/1471-2288-9-34
Shea, 2007, Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews, BMC Med Res Methodol, 7, 10, 10.1186/1471-2288-7-10
2008
Shigematsu, 2005, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers, J Natl Cancer Inst, 97, 339, 10.1093/jnci/dji055
Mitsudomi, 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, 11, 121, 10.1016/S1470-2045(09)70364-X
Rosell, 2009, Screening for epidermal growth factor receptor mutations in lung cancer, N Engl J Med, 361, 958, 10.1056/NEJMoa0904554
Douillard, 2010, Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial, J Clin Oncol, 28, 744, 10.1200/JCO.2009.24.3030
Morinaga, 2008, Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer, Cancer Sci, 99, 2455, 10.1111/j.1349-7006.2008.00962.x
Sun, 2010, Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases, J Clin Oncol, 28, 4616, 10.1200/JCO.2010.29.6038
Zhang, 2010, Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression, Mol Cancer, 9, 188, 10.1186/1476-4598-9-188
Girard, 2012, Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma, Eur Respir J, 39, 366, 10.1183/09031936.00010111
Dogan, 2012, Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers, Clin Cancer Res, 18, 6169, 10.1158/1078-0432.CCR-11-3265
National Comprehensive Cancer Network. The NCCN clinical practice guidelines in oncology (NCCN guidelines) for non-small cell lung cancer. Version 3.2012. Published 2012. Available online at http://www.nccn.org, last accessed October 16, 2012.
Liu, 2008, EGFR mutations are more frequent in well-differentiated than in poor-differentiated lung adenocarcinomas, Pathol Oncol Res, 14, 373, 10.1007/s12253-008-9113-1
Rekhtman, 2012, Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations, Clin Cancer Res, 18, 1167, 10.1158/1078-0432.CCR-11-2109
Ohtsuka, 2006, Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma, J Thorac Oncol, 1, 787, 10.1016/S1556-0864(15)30407-X
Kosaka, 2004, Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications, Cancer Res, 64, 8919, 10.1158/0008-5472.CAN-04-2818
Takahashi, 2010, Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene, Ann Surg Oncol, 17, 889, 10.1245/s10434-009-0808-7
Yoshida, 2011, Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component, Lung Cancer, 72, 309, 10.1016/j.lungcan.2010.09.013
Chaft, 2012, ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma, J Thorac Oncol, 7, 768, 10.1097/JTO.0b013e31824c9485
Sartori, 2009, EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors, Am J Clin Pathol, 131, 478, 10.1309/AJCPH0TRMPXVZW2F
Sugio, 2006, Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking, Br J Cancer, 94, 896, 10.1038/sj.bjc.6603040
Tsao, 2006, Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer, J Thorac Oncol, 1, 231, 10.1016/S1556-0864(15)31573-2
Marchetti, 2005, EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment, J Clin Oncol, 23, 857, 10.1200/JCO.2005.08.043
Tam, 2006, Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features, Clin Cancer Res, 12, 1647, 10.1158/1078-0432.CCR-05-1981
Pao, 2004, EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc Natl Acad Sci USA, 101, 13306, 10.1073/pnas.0405220101
Huang, 2004, High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan, Clin Cancer Res, 10, 8195, 10.1158/1078-0432.CCR-04-1245
Sonobe, 2005, Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma, Br J Cancer, 93, 355, 10.1038/sj.bjc.6602707
Tokumo, 2005, The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers, Clin Cancer Res, 11, 1167, 10.1158/1078-0432.1167.11.3
Tomizawa, 2005, Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer, Clin Cancer Res, 11, 6816, 10.1158/1078-0432.CCR-05-0441
Qin, 2005, Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy, Cell Res, 15, 212, 10.1038/sj.cr.7290289
Han, 2005, Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib, J Clin Oncol, 23, 2493, 10.1200/JCO.2005.01.388
Cappuzzo, 2005, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer, J Natl Cancer Inst, 97, 643, 10.1093/jnci/dji112
Wu, 2008, Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications, Cancer, 113, 3199, 10.1002/cncr.23925
Chou, 2005, Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer, Clin Cancer Res, 11, 3750, 10.1158/1078-0432.CCR-04-1981
Park, 2009, Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer, J Thorac Oncol, 4, 809, 10.1097/JTO.0b013e3181a94af4
Park, 2009, Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung, J Korean Med Sci, 24, 448, 10.3346/jkms.2009.24.3.448
Gandara, 2010, Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer, J Thorac Oncol, 5, 1933, 10.1097/JTO.0b013e3181fd418d
Tsao, 2011, Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer, J Thorac Oncol, 6, 139, 10.1097/JTO.0b013e3181fd83a4
Rekhtman, 2011, Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens, Mod Pathol, 24, 1348, 10.1038/modpathol.2011.92
Rekhtman, 2011, Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing, J Thorac Oncol, 6, 451, 10.1097/JTO.0b013e31820517a3
Travis, 2011, International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma, J Thorac Oncol, 6, 244, 10.1097/JTO.0b013e318206a221
Fukui, 2007, Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung, Cancer Sci, 98, 1714, 10.1111/j.1349-7006.2007.00600.x
Morinaga, 2007, Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation, Lung Cancer, 58, 411, 10.1016/j.lungcan.2007.05.014
Tatematsu, 2008, Epidermal growth factor receptor mutations in small cell lung cancer, Clin Cancer Res, 14, 6092, 10.1158/1078-0432.CCR-08-0332
Araki, 2005, Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer, Lung Cancer, 48, 141, 10.1016/j.lungcan.2004.10.012
Okamoto, 2006, EGFR mutation in gefitinib-responsive small-cell lung cancer, Ann Oncol, 17, 1028, 10.1093/annonc/mdj114
Zakowski, 2006, EGFR mutations in small-cell lung cancers in patients who have never smoked, N Engl J Med, 355, 213, 10.1056/NEJMc053610
Arcila, 2011, Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay, Clin Cancer Res, 17, 1169, 10.1158/1078-0432.CCR-10-2277
Balak, 2006, Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors, Clin Cancer Res, 12, 6494, 10.1158/1078-0432.CCR-06-1570
Dahse, 2008, PCR-based testing for therapy-related EGFR mutations in patients with non-small cell lung cancer, Anticancer Res, 28, 2265
Macarenco, 2008, Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study, Mod Pathol, 21, 1168, 10.1038/modpathol.2008.113
Dahse, 2009, Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas, Br J Cancer, 100, 623, 10.1038/sj.bjc.6604875
Han, 2008, Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment, Lung Cancer, 61, 30, 10.1016/j.lungcan.2007.11.014
Rossi, 2009, Biological prognostic and predictive factors in lung cancer, Oncology, 77, 90, 10.1159/000258500
Rekhtman N, Tafe LJ, Chaft JE, et al. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma [Epub]. Mod Pathol http://dx.doi.org/10.1038/modpathol.2012.195
Rickman, 2009, Analysis of ErbB receptors in pulmonary carcinoid tumors, Clin Cancer Res, 15, 3315, 10.1158/1078-0432.CCR-08-2549
Paik, 2012, Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma, Lung Cancer, 76, 403, 10.1016/j.lungcan.2011.11.008
Yatabe, 2011, Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma, J Clin Oncol, 29, 2972, 10.1200/JCO.2010.33.3906
Girard, 2010, Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines, Chest, 137, 46, 10.1378/chest.09-0325
Casorzo, 2009, Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer, Diagn Pathol, 4, 36, 10.1186/1746-1596-4-36
Sholl, 2009, Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers, Cancer Res, 69, 8341, 10.1158/0008-5472.CAN-09-2477
Liang, 2010, Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas, BMC Cancer, 10, 376, 10.1186/1471-2407-10-376
Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, 366, 883, 10.1056/NEJMoa1113205
Keedy, 2011, American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy, J Clin Oncol, 29, 2121, 10.1200/JCO.2010.31.8923
Marks, 2008, Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma, J Thorac Oncol, 3, 111, 10.1097/JTO.0b013e318160c607
D'Angelo, 2012, Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib, J Thorac Oncol, 7, 1815, 10.1097/JTO.0b013e31826bb7b2
Mitsudomi, 2011, Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?, Lancet Oncol, 12, 710, 10.1016/S1470-2045(11)70194-2
Fukuoka, 2011, Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS), J Clin Oncol, 29, 2866, 10.1200/JCO.2010.33.4235
Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530
Srinivasan, 2002, Effect of fixatives and tissue processing on the content and integrity of nucleic acids, Am J Pathol, 161, 1961, 10.1016/S0002-9440(10)64472-0
Gillespie, 2002, Evaluation of non-formalin tissue fixation for molecular profiling studies, Am J Pathol, 160, 449, 10.1016/S0002-9440(10)64864-X
Pirker, 2010, Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop, J Thorac Oncol, 5, 1706, 10.1097/JTO.0b013e3181f1c8de
Wong, 1998, Mutations in BRCA1 from fixed, paraffin-embedded tissue can be artifacts of preservation, Cancer Genet Cytogenet, 107, 21, 10.1016/S0165-4608(98)00079-X
Akbari, 2005, Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner, J Mol Diagn, 7, 36, 10.1016/S1525-1578(10)60006-2
Williams, 1999, A high frequency of sequence alterations is due to formalin fixation of archival specimens, Am J Pathol, 155, 1467, 10.1016/S0002-9440(10)65461-2
Wolff, 2007, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, Arch Pathol Lab Med, 131, 18, 10.5858/2007-131-18-ASOCCO
Aisner DL, Deshpande C, Baloch Z, et al. Evaluation of EGFR mutation status in cytology specimens: an institutional experience [published online ahead of print November 18, 2011]. Diagn Cytopathol. doi:10.1002/dc.21851
Malapelle, 2011, Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review, Diagn Cytopathol, 39, 703, 10.1002/dc.21512
da Cunha Santos, 2011, EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities, Cancer Cytopathol, 119, 80, 10.1002/cncy.20150
Fiallo, 1992, Effects of fixation on polymerase chain reaction detection of Mycobacterium leprae, J Clin Microbiol, 30, 3095, 10.1128/JCM.30.12.3095-3098.1992
Wilson, 1997, Inhibition and facilitation of nucleic acid amplification, Appl Environ Microbiol, 63, 3741, 10.1128/AEM.63.10.3741-3751.1997
Baloglu, 2008, The effects of tissue fixation alternatives on DNA content: a study on normal colon tissue, Appl Immunohistochem Mol Morphol, 16, 485, 10.1097/PAI.0b013e31815dffa6
Moore, 2002, Fixation and decalcification of adult zebrafish for histological, immunocytochemical, and genotypic analysis, Biotechniques, 32, 296, 10.2144/02322st03
College of American Pathologists. CAP Laboratory accreditation checklists. http://www.cap.org/apps/cap.portal. Last accessed April 11, 2012
Betz, 2011, The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma, Am J Clin Pathol, 136, 564, 10.1309/AJCP84TUTQOSUONG
Billah, 2011, EGFR and KRAS mutations in lung carcinoma, Cancer Cytopathol, 119, 111, 10.1002/cncy.20151
Chen, 2008, Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer, Acta Radiol, 49, 991, 10.1080/02841850802294410
Boldrini, 2007, Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis, J Thorac Oncol, 2, 1086, 10.1097/JTO.0b013e31815ba1fa
Fassina, 2009, Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis, J Clin Pathol, 62, 1096, 10.1136/jcp.2009.067587
Smouse, 2009, EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer, Cancer Cytopathol, 117, 67, 10.1002/cncy.20011
Lozano, 2011, Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes, Oncologist, 16, 877, 10.1634/theoncologist.2010-0155
Janne, 2006, A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening, Clin Cancer Res, 12, 751, 10.1158/1078-0432.CCR-05-2047
Pan, 2005, Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas, J Mol Diagn, 7, 396, 10.1016/S1525-1578(10)60569-7
Sasaki, 2005, EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler, Clin Cancer Res, 11, 2924, 10.1158/1078-0432.CCR-04-1904
Croft, 2008, Performance of whole-genome amplified DNA isolated from serum and plasma on high-density single nucleotide polymorphism arrays, J Mol Diagn, 10, 249, 10.2353/jmoldx.2008.070155
Endo, 2005, Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay, Lung Cancer, 50, 375, 10.1016/j.lungcan.2005.08.009
Hoshi, 2007, Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process, Clin Cancer Res, 13, 4974, 10.1158/1078-0432.CCR-07-0509
Heideman, 2009, A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes, Cell Oncol, 31, 329
Miyazawa, 2008, Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation, Cancer Sci, 99, 595, 10.1111/j.1349-7006.2007.00706.x
Li, 2008, EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression, J Mol Diagn, 10, 242, 10.2353/jmoldx.2008.070178
Soh, 2009, Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells, PLoS ONE, 4, e7464, 10.1371/journal.pone.0007464
Thunnissen, 2011, EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy, J Clin Pathol, 64, 884, 10.1136/jclinpath-2011-200163
Eberhard, 2008, Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting, J Clin Oncol, 26, 983, 10.1200/JCO.2007.12.9858
Sieben, 2000, PCR artifacts in LOH and MSI analysis of microdissected tumor cells, Hum Pathol, 31, 1414, 10.1016/S0046-8177(00)80013-1
Molina-Vila, 2008, A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells, J Thorac Oncol, 3, 1224, 10.1097/JTO.0b013e318189f579
Takano, 2005, Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer, J Clin Oncol, 23, 6829, 10.1200/JCO.2005.01.0793
Horiike, 2007, Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer, Chest, 131, 1628, 10.1378/chest.06-1673
Yatabe, 2006, A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer, J Mol Diagn, 8, 335, 10.2353/jmoldx.2006.050104
Miyamae, 2010, Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue, J Mol Diagn, 12, 257, 10.2353/jmoldx.2010.090105
Kawada, 2008, An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients, J Thorac Oncol, 3, 1096, 10.1097/JTO.0b013e318186fadd
van Eijk, 2011, Rapid KRAS. EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR, PLoS ONE, 6, e17791, 10.1371/journal.pone.0017791
Do, 2008, High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies, BMC Cancer, 8, 142, 10.1186/1471-2407-8-142
Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med, 2, e73, 10.1371/journal.pmed.0020073
Santis, 2011, Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR, PLoS ONE, 6, e25191, 10.1371/journal.pone.0025191
Sueoka, 2007, Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients, J Cancer Res Clin Oncol, 133, 93, 10.1007/s00432-006-0144-2
Engelman, 2006, The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors, Clin Cancer Res, 12, 4372s, 10.1158/1078-0432.CCR-06-0795
Jiang, 2008, EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance, Int J Cancer, 123, 2480, 10.1002/ijc.23868
Krypuy, 2006, High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: kRAS codon 12 and 13 mutations in non-small cell lung cancer, BMC Cancer, 6, 295, 10.1186/1471-2407-6-295
Kuang, 2009, Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer, Clin Cancer Res, 15, 2630, 10.1158/1078-0432.CCR-08-2592
Ogino, 2005, Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer, Clin Cancer Res, 11, 6650, 10.1158/1078-0432.CCR-05-0738
Ohnishi, 2006, A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma, Diagn Mol Pathol, 15, 101, 10.1097/00019606-200606000-00007
Pham, 2006, Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas, J Clin Oncol, 24, 1700, 10.1200/JCO.2005.04.3224
Su, 2011, A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer, J Mol Diagn, 13, 74, 10.1016/j.jmoldx.2010.11.010
Azzoli, 2009, American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer, J Clin Oncol, 27, 6251, 10.1200/JCO.2009.23.5622
Bosari, 1995, Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis: a comparative study of radioactive and nonradioactive silver-stained SSCP analysis, Diagn Mol Pathol, 4, 249, 10.1097/00019606-199512000-00004
Fan, 2001, Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells, Int J Oncol, 18, 1023
Fukui, 2008, Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer, Clin Cancer Res, 14, 4751, 10.1158/1078-0432.CCR-07-5207
Kimura, 2006, Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer, Clin Cancer Res, 12, 3915, 10.1158/1078-0432.CCR-05-2324
Newton, 1989, Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS), Nucleic Acids Res, 17, 2503, 10.1093/nar/17.7.2503
Takano, 2007, Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib, Clin Cancer Res, 13, 5385, 10.1158/1078-0432.CCR-07-0627
Whitcombe, 1999, Detection of PCR products using self-probing amplicons and fluorescence, Nature Biotechnol, 17, 804, 10.1038/11751
Li, 2009, Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR, Clin Chem, 55, 748, 10.1373/clinchem.2008.113381
Beadling, 2012, Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping, J Mol Diagn
Buttitta, 2013, Effective assessment of EGFR mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing, Clin Cancer Res, 19, 691, 10.1158/1078-0432.CCR-12-1958
Querings, 2011, Benchmarking of mutation diagnostics in clinical lung cancer specimens, PLoS ONE, 6, e19601, 10.1371/journal.pone.0019601
Tsiatis, 2010, Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications, J Mol Diagn, 12, 425, 10.2353/jmoldx.2010.090188
Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314
Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938
Tsao, 2005, Erlotinib in lung cancer—molecular and clinical predictors of outcome, N Engl J Med, 353, 133, 10.1056/NEJMoa050736
Ward, 1998, Restriction endonuclease-mediated selective polymerase chain reaction: a novel assay for the detection of K-ras mutations in clinical samples, Am J Pathol, 153, 373, 10.1016/S0002-9440(10)65581-2
Diagnostic Innovations. Urgent field safety notice 001. http://www.swissmedic.ch/recalllists_dl/02354/Vk_20090603_14-e1.pdf. Published 2009. Last accessed June 7, 2011
He, 2012, EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma, Clin Cancer Res, 18, 1790, 10.1158/1078-0432.CCR-11-2361
Yasuda, 2012, EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications, Lancet Oncol, 13, e23, 10.1016/S1470-2045(11)70129-2
Kobayashi, 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N Engl J Med, 352, 786, 10.1056/NEJMoa044238
Arcila, 2013, EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics, Mol Cancer Ther, 12, 220, 10.1158/1535-7163.MCT-12-0620
Miller, 2008, Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib, J Clin Oncol, 26, 1472, 10.1200/JCO.2007.13.0062
Sholl, 2010, EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH. CISH, and immunohistochemistry Am J, Clin Pathol, 133, 922, 10.1309/AJCPST1CTHZS3PSZ
Khambata-Ford, 2010, Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer, J Clin Oncol, 28, 918, 10.1200/JCO.2009.25.2890
Yu, 2009, Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer, Clin Cancer Res, 15, 3023, 10.1158/1078-0432.CCR-08-2739
Kato, 2010, Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations, J Thorac Oncol, 5, 1551, 10.1097/JTO.0b013e3181e9da60
Kawahara, 2010, Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis, Clin Cancer Res, 16, 3163, 10.1158/1078-0432.CCR-09-3239
Brevet, 2010, Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR, J Mol Diagn, 12, 169, 10.2353/jmoldx.2010.090140
Kozu, 2011, The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma, Lung Cancer, 73, 45, 10.1016/j.lungcan.2010.11.003
Kawahara, 2011, Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry, Lung Cancer, 74, 35, 10.1016/j.lungcan.2011.02.002
Hasanovic, 2012, Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma, Lung Cancer, 77, 299, 10.1016/j.lungcan.2012.04.004
Zhu, 2008, Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21, J Clin Oncol, 26, 4268, 10.1200/JCO.2007.14.8924
Testa, 1992, Chromosome abnormalities in human non-small cell lung cancer, Cancer Res, 52, 2702s
Hirsch, 2005, Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study, J Clin Oncol, 23, 6838, 10.1200/JCO.2005.01.2823
Inoue, 2009, First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy, J Clin Oncol, 27, 1394, 10.1200/JCO.2008.18.7658
Lee, 2009, Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma, J Cancer Res Clin Oncol, 135, 1647, 10.1007/s00432-009-0611-7
Soh, 2007, Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer, Int J Cancer, 121, 1162, 10.1002/ijc.22818
Broet, 2011, Genomic profiles specific to patient ethnicity in lung adenocarcinoma, Clin Cancer Res, 17, 3542, 10.1158/1078-0432.CCR-10-2185
Leidner, 2009, Genetic abnormalities of the EGFR pathway in African American patients with non-small-cell lung cancer, J Clin Oncol, 27, 5620, 10.1200/JCO.2009.23.1431
Reinersman, 2011, Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans, J Thorac Oncol, 6, 28, 10.1097/JTO.0b013e3181fb4fe2
Riely, 2008, Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma, Clin Cancer Res, 14, 5731, 10.1158/1078-0432.CCR-08-0646
Thu, 2012, Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability, PLoS ONE, 7, e33003, 10.1371/journal.pone.0033003
Massarelli, 2007, KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer, Clin Cancer Res, 13, 2890, 10.1158/1078-0432.CCR-06-3043
Ludovini, 2011, Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer, J Thorac Oncol, 6, 707, 10.1097/JTO.0b013e31820a3a6b
Hirsch, 2007, Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib, Ann Oncol, 18, 752, 10.1093/annonc/mdm003
Endoh, 2006, PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients, J Thorac Oncol, 1, 629
Hirsch, 2011, A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer, J Clin Oncol, 29, 3567, 10.1200/JCO.2010.34.4929
Inukai, 2006, Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer, Cancer Res, 66, 7854, 10.1158/0008-5472.CAN-06-1951
Tiseo, 2010, Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers, Lung Cancer, 67, 355, 10.1016/j.lungcan.2009.04.021
Lara-Guerra, 2009, Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer, J Clin Oncol, 27, 6229, 10.1200/JCO.2009.22.3370
Jackman, 2009, Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials, Clin Cancer Res, 15, 5267, 10.1158/1078-0432.CCR-09-0888
van Zandwijk, 2007, EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer, Ann Oncol, 18, 99, 10.1093/annonc/mdl323
Brugger, 2011, Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer, J Clin Oncol, 29, 4113, 10.1200/JCO.2010.31.8162
Endo, 2006, Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy, Oncol Rep, 16, 533
O'Byrne, 2011, Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study, Lancet Oncol, 12, 795, 10.1016/S1470-2045(11)70189-9
Bean, 2007, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib, Proc Natl Acad Sci USA, 104, 20932, 10.1073/pnas.0710370104
Engelman, 2008, Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer, Clin Cancer Res, 14, 2895, 10.1158/1078-0432.CCR-07-2248
Jackman, 2010, Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer, J Clin Oncol, 28, 357, 10.1200/JCO.2009.24.7049
Engelman, 2006, Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer, J Clin Invest, 116, 2695, 10.1172/JCI28656
Onitsuka, 2010, Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status Lung Cancer, 68, 198, 10.1016/j.lungcan.2009.05.022
Chmielecki, 2011, Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling, Sci Transl Med, 3, 90ra59, 10.1126/scitranslmed.3002356
Oxnard, 2012, Screening for germline EGFR T790M mutations through lung cancer genotyping, J Thorac Oncol, 7, 1049, 10.1097/JTO.0b013e318250ed9d
Bell, 2005, Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials, J Clin Oncol, 23, 8081, 10.1200/JCO.2005.02.7078
Nguyen, 2009, Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway, Clin Lung Cancer, 10, 281, 10.3816/CLC.2009.n.039
Sequist, 2011, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci Transl Med, 3, 75ra26, 10.1126/scitranslmed.3002003
Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478
Rikova, 2007, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer, Cell, 131, 1190, 10.1016/j.cell.2007.11.025
Takeuchi, 2009, KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer, Clin Cancer Res, 15, 3143, 10.1158/1078-0432.CCR-08-3248
Camidge, 2010, Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment, Clin Cancer Res, 16, 5581, 10.1158/1078-0432.CCR-10-0851
Perner, 2008, EML4-ALK fusion lung cancer: a rare acquired event, Neoplasia, 10, 298, 10.1593/neo.07878
Wiktor, 2006, Preclinical validation of fluorescence in situ hybridization assays for clinical practice, Genet Med, 8, 16, 10.1097/01.gim.0000195645.00446.61
Mascarello, 2011, Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization, Genet Med, 13, 667, 10.1097/GIM.0b013e3182227295
Mino-Kenudson, 2010, A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry, Clin Cancer Res, 16, 1561, 10.1158/1078-0432.CCR-09-2845
Horn, 2009, EML4-ALK: honing in on a new target in non-small-cell lung cancer, J Clin Oncol, 27, 4232, 10.1200/JCO.2009.23.6661
Yi, 2011, Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: iHC score algorithm for FISH, J Thorac Oncol, 6, 459, 10.1097/JTO.0b013e318209edb9
Togashi, 2012, KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only, PLoS ONE, 7, e31323, 10.1371/journal.pone.0031323
Heuckmann, 2011, ALK mutations conferring differential resistance to structurally diverse ALK inhibitors, Clin Cancer Res, 17, 7394, 10.1158/1078-0432.CCR-11-1648
Sasaki, 2010, The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers, Cancer Res, 70, 10038, 10.1158/0008-5472.CAN-10-2956
Sasaki, 2011, A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors, Cancer Res, 71, 6051, 10.1158/0008-5472.CAN-11-1340
Choi, 2010, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors, N Engl J Med, 363, 1734, 10.1056/NEJMoa1007478
Doebele, 2012, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer, Clin Cancer Res, 18, 1472, 10.1158/1078-0432.CCR-11-2906
Katayama, 2012, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers, Sci Transl Med, 4, 120ra17, 10.1126/scitranslmed.3003316
Tiseo, 2011, EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations, Lung Cancer, 71, 241, 10.1016/j.lungcan.2010.11.014
Kuo, 2010, Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation, J Thorac Oncol, 5, 2039, 10.1097/JTO.0b013e3181f43274
1992, Clinical laboratory improvement amendments of 1988: final rule, Fed Regist, 57, 7001
Jennings, 2012, Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease, Arch Pathol Lab Med, 136, 33, 10.5858/arpa.2011-0136-OA
Pont-Kingdon, 2012, Design and analytical validation of clinical DNA sequencing assays, Arch Pathol Lab Med, 136, 41, 10.5858/arpa.2010-0623-OA
Saxe, 2012, Validation of fluorescence in situ hybridization using an analyte-specific reagent for detection of abnormalities involving the mixed lineage leukemia gene, Arch Pathol Lab Med, 136, 47, 10.5858/arpa.2010-0645-SA
Kamel-Reid, 2012, Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma, Arch Pathol Lab Med, 136, 26, 10.5858/arpa.2011-0220-OA
Halling, 2012, Test verification and validation for molecular diagnostic assays, Arch Pathol Lab Med, 136, 11, 10.5858/arpa.2011-0212-ED
Fitzgibbons, 2010, Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays, Arch Pathol Lab Med, 134, 930, 10.5858/134.6.930
Penzel, 2011, EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC, Virchows Arch, 458, 95, 10.1007/s00428-010-1000-y
Spanish Division of the International Academy of Pathology. http://www.seap.es. Last accessed April 28, 2012
European Molecular Genetics Quality Network. http://www.emqn.org/emqn/Home. Last accessed April 28, 2012
European Society of Pathology. http://www.esp-pathology.org. Last accessed April 28, 2012
Feng, 2012, MET signaling: novel targeted inhibition and its clinical development in lung cancer, J Thorac Oncol, 7, 459, 10.1097/JTO.0b013e3182417e44
Dziadziuszko, 2012, Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer, J Thorac Oncol, 7, 340, 10.1097/JTO.0b013e318240ca0d
De Greve, 2012, Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu, Lung Cancer, 76, 123, 10.1016/j.lungcan.2012.01.008
Arcila, 2012, Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas, Clin Cancer Res, 18, 4910, 10.1158/1078-0432.CCR-12-0912
Lipson, 2012, Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies, Nat Med, 18, 382, 10.1038/nm.2673
Roychowdhury, 2011, Personalized oncology through integrative high-throughput sequencing: a pilot study, Sci Transl Med, 3, 111ra121, 10.1126/scitranslmed.3003161
Ahn, 2008, Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?, Clin Cancer Res, 14, 3860, 10.1158/1078-0432.CCR-07-4608
Cappuzzo, 2007, Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial, J Clin Oncol, 25, 2248, 10.1200/JCO.2006.09.4300
Choi, 2011, Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study, Anticancer Res, 31, 3457
Cohen, 2010, Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors, Cancer, 116, 4309, 10.1002/cncr.25214
Cortes-Funes, 2005, Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients, Ann Oncol, 16, 1081, 10.1093/annonc/mdi221
Han, 2012, First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung, J Clin Oncol, 30, 1122, 10.1200/JCO.2011.36.8456
Harada, 2011, Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry, Oncogene, 30, 1744, 10.1038/onc.2010.545
Hotta, 2007, Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer, J Thorac Oncol, 2, 632, 10.1097/JTO.0b013e318074bc0d
Hsieh, 2006, Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer, Lung Cancer, 53, 311, 10.1016/j.lungcan.2006.06.005
Jackman, 2007, Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer, J Clin Oncol, 25, 760, 10.1200/JCO.2006.07.5754
Janne, 2012, ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma, J Clin Oncol, 30, 878, 10.1200/JCO.2011.39.4197
Jian, 2010, Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer, J Cancer Res Clin Oncol, 136, 1341, 10.1007/s00432-010-0785-z
Kim, 2005, Predictors of the response to gefitinib in refractory non-small cell lung cancer, Clin Cancer Res, 11, 2244, 10.1158/1078-0432.CCR-04-2081
Kim, 2012, Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy, Lung Cancer, 75, 82, 10.1016/j.lungcan.2011.05.022
Kondo, 2005, Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery, Lung Cancer, 50, 385, 10.1016/j.lungcan.2005.06.008
Lee, 2011, Phase II study of erlotinib for chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets, Cancer Chemother Pharmacol, 67, 35, 10.1007/s00280-010-1280-6
Oshita, 2006, Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer, Br J Cancer, 95, 1070, 10.1038/sj.bjc.6603396
Porta, 2011, Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation, Eur Respir J, 37, 624, 10.1183/09031936.00195609
Rizvi, 2011, Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene, Clin Cancer Res, 17, 3500, 10.1158/1078-0432.CCR-10-2102
Sasaki, 2008, Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer, J Cancer Res Clin Oncol, 134, 569, 10.1007/s00432-007-0320-z
Satouchi, 2007, Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib, Br J Cancer, 96, 1191, 10.1038/sj.bjc.6603710
Sequist, 2007, Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing, Oncologist, 12, 90, 10.1634/theoncologist.12-1-90
Sutani, 2006, Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp, Br J Cancer, 95, 1483, 10.1038/sj.bjc.6603466
Taron, 2005, Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas, Clin Cancer Res, 11, 5878, 10.1158/1078-0432.CCR-04-2618
Uramoto, 2006, Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese, Lung Cancer, 51, 71, 10.1016/j.lungcan.2005.08.006
Wang, 2008, EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients, Onkologie, 31, 174, 10.1159/000116736
Xu, 2009, EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib, J Cancer Res Clin Oncol, 135, 771, 10.1007/s00432-008-0512-1
Yang, 2008, Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy, J Clin Oncol, 26, 2745, 10.1200/JCO.2007.15.6695
Wu, 2011, Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations, Medicine (Baltimore), 90, 159, 10.1097/MD.0b013e31821a16f4
Argiris, 2006, Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story, J Thorac Oncol, 1, 52
Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X
Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL. CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 735, 10.1016/S1470-2045(11)70184-X
Yang, 2012, LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations, J Clin Oncol, 30, LBA7500, 10.1200/jco.2012.30.18_suppl.lba7500
Asahina, 2006, A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations, Br J Cancer, 95, 998, 10.1038/sj.bjc.6603393
Bae, 2007, EGFR. ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients, Cancer Genet Cytogenet, 173, 107, 10.1016/j.cancergencyto.2006.10.007
Haneda, 2006, A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma, Jpn J Clin Oncol, 36, 69, 10.1093/jjco/hyi228
Inoue, 2006, Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations, J Clin Oncol, 24, 3340, 10.1200/JCO.2005.05.4692
Kang, 2007, Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung, Cancer, 109, 581, 10.1002/cncr.22413
Riely, 2006, Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib, Clin Cancer Res, 12, 839, 10.1158/1078-0432.CCR-05-1846
Soung, 2005, Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas, Virchows Arch, 446, 483, 10.1007/s00428-005-1254-y
Sugio, 2009, Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations, Lung Cancer, 64, 314, 10.1016/j.lungcan.2008.09.010
Sunaga, 2007, Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy, Lung Cancer, 56, 383, 10.1016/j.lungcan.2007.01.025
Tang, 2008, Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas, Cancer Prev Res (Phila), 1, 192, 10.1158/1940-6207.CAPR-08-0032
Cote, 2011, Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer, J Thorac Oncol, 6, 627, 10.1097/JTO.0b013e31820a0ec0
Moiseyenko, 2010, High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma, Onkologie, 33, 231, 10.1159/000302729
Sahoo, 2011, Screening for EGFR mutations in lung cancer, a report from India, Lung Cancer, 73, 316, 10.1016/j.lungcan.2011.01.004
Otani, 2008, Detection of EGFR gene mutations using the wash fluid of CT-guided biopsy needle in NSCLC patients, J Thorac Oncol, 3, 472, 10.1097/JTO.0b013e31816de2cd
Dacic, 2010, Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas, Mod Pathol, 23, 159, 10.1038/modpathol.2009.154
Blons, 2006, Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation, Am J Surg Pathol, 30, 1309, 10.1097/01.pas.0000213285.65907.31
Takeuchi, 2008, Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts, Clin Cancer Res, 14, 6618, 10.1158/1078-0432.CCR-08-1018
Lee, 2010, Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers, J Thorac Oncol, 5, 1734, 10.1097/JTO.0b013e3181f0beca
Miyamae, 2011, Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma, Oncol Rep, 25, 921
2012, Comprehensive genomic characterization of squamous cell lung cancers, Nature, 489, 519, 10.1038/nature11404
Sun, 2011, Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice, J Exp Clin Cancer Res, 30, 30, 10.1186/1756-9966-30-30
Gombos, 2010, A comparative study of EGFR mutation screening methods in non-small cell carcinoma of lung, Bratisl Lek Listy, 111, 365
Naoki, 2011, The PCR-invader method (structure-specific 5′ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing, Int J Clin Oncol, 16, 335, 10.1007/s10147-011-0187-5
Dufort, 2011, Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC, J Exp Clin Cancer Res, 30, 57, 10.1186/1756-9966-30-57
Cohen, 2006, Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer, Cancer, 107, 2858, 10.1002/cncr.22331
Hlinkova, 2011, Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis, Mol Diagn Ther, 15, 21, 10.1007/BF03257190
Nakajima, 2007, Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration, Chest, 132, 597, 10.1378/chest.07-0095
Soh, 2006, Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer, Int J Cancer, 119, 2353, 10.1002/ijc.22190
Bamford, 2004, The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website, Br J Cancer, 91, 355, 10.1038/sj.bjc.6601894
De Pas, 2001, Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine, Lung Cancer, 31, 267, 10.1016/S0169-5002(00)00176-8
Murray, 2008, Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database, J Thorac Oncol, 3, 832, 10.1097/JTO.0b013e31818071f3
Pinter, 2008, Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry, J Mol Diagn, 10, 160, 10.2353/jmoldx.2008.070125
Sequist, 2008, First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations, J Clin Oncol, 26, 2442, 10.1200/JCO.2007.14.8494
Sone, 2007, Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer, Cancer, 109, 1836, 10.1002/cncr.22593
Ichihara, 2007, The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer, Int J Cancer, 120, 1239, 10.1002/ijc.22513
Takezawa, 2012, HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation, Cancer Discov, 2, 922, 10.1158/2159-8290.CD-12-0108
Ju, 2012, A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing, Genome Res, 22, 436, 10.1101/gr.133645.111